Paper Details

  1. Home
  2. Paper Details

Decision-making for PCV in adults.

Author: IsturizRaul E, JodarLuis, McLaughlinJohn M, SwerdlowDavid L

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Overview

Despite widespread use of PCV13 in children, a significant burden of pneumococcal pneumonia still exists in adults, suggesting continued vaccination is necessary.
Paper Details　
Original Abstract of the Article :
Thirteen-valent pneumococcal conjugate vaccine (PCV13) was licensed in adults to address the unmet medical need of vaccine-type community acquired pneumonia (CAP) and the limitations of previous plain-polysaccharide vaccines. Since then, some have questioned the utility of adult PCV13 use, arguing t...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6605720/

データ提供：米国国立医学図書館（NLM）

Pneumococcal Conjugate Vaccine (PCV13): A Crucial Tool for Adult Health

The fight against infectious diseases is a constant challenge, with researchers and healthcare providers working tirelessly to protect individuals from harmful pathogens. This study examines the role of the pneumococcal conjugate vaccine (PCV13) in adults, particularly in preventing community-acquired pneumonia (CAP).

Navigating the Shifting Sands of Vaccine Effectiveness

The study delves into the debate surrounding the effectiveness of PCV13 in adults, considering the widespread use of the vaccine in children and the potential for indirect protection. It highlights the significant burden of pneumococcal disease in adults, particularly those with weakened immune systems. The research emphasizes the importance of direct vaccination in adults, as indirect protection alone may not be sufficient.

Protecting Adults From Pneumococcal Infections

The study provides compelling evidence for the continued use of PCV13 in adults, particularly those at increased risk for pneumococcal disease. It emphasizes the ethical and pragmatic benefits of vaccination, suggesting that continued use of PCV13 is essential for protecting adults from this potentially serious illness.

Dr.Camel's Conclusion

This research, like a sturdy caravan navigating a challenging desert, brings important insights into the role of pneumococcal conjugate vaccine (PCV13) in protecting adults. It underscores the importance of vaccination as a key tool for preventing pneumococcal disease, ensuring the health and well-being of adults.
Date :
  1. Date Completed 2020-02-26
  2. Date Revised 2020-03-09
Further Info :

Pubmed ID

30352017

DOI: Digital Object Identifier

PMC6605720

Related Literature

Article Analysis
・Effects of pneumococcal conjugate vaccine (pcv13
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.